FDA Website Confirms Cyberonics' Depression Panel Date HOUSTON, April 26 /PRNewswire-FirstCall/ -- Cyberonics, Inc. today announced that FDA confirmed on its website (http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfadvisory/details.cfm?mtg= 512 ) that a meeting of its Neurological Devices Advisory Panel will occur on June 15, 2004 to review Cyberonics' PMA-Supplement (PMA-S) seeking approval to market the VNS Therapy(TM) System "as an adjunctive long-term treatment of chronic or recurrent depression for patients over the age of 18 who are experiencing a major depressive episode that has not had an adequate response to two or more adequate antidepressant treatments." DATASOURCE: Cyberonics, Inc. CONTACT: Pamela Westbrook, Vice President of Finance and CFO of Cyberonics, Inc., +1-281-228-7200, or fax, +1-281-218-9332, or ; or Helen Shik, Vice President of Schwartz Communications, +1-781-684-0770, ext. 6587, or fax, +1-781-684-6500, or , for Cyberonics, Inc. Web site: http://www.cyberonics.com/

Copyright